Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: A post hoc pooled analysis was undertaken to evaluate the safety of saxagliptin in patients with type 2 diabetes mellitus, with attention to events of special interest for dipeptidyl peptidase‐4 inhibitors. Methods: Pooled analyses were performed for 20 randomized controlled studies (N = 9156) of saxagliptin as monotherapy or add‐on therapy, and a subset of 11 saxagliptin + metformin studies. Adverse events and events of special interest (gastrointestinal adverse events, infections, hypersensitivity, pancreatitis, skin lesions, lymphopenia, thrombocytopenia, hypoglycaemia, bone fracture, severe cutaneous adverse reactions, opportunistic infection, angioedema, malignancy, worsening renal function, and specific laboratory events) were assessed; incidence rates (events/100 person‐years) and incidence rates ratios (saxagliptin/control) were calculated (Mantel–Haenszel method). Results: In both pooled datasets, the incidence rates for deaths, serious adverse events, discontinuations due to adverse events, pancreatitis, malignancy, and most other events of special interest, excepting bone fractures and hypersensitivity, were similar between treatments, with 95% confidence intervals (CIs) for incidence rates ratios including 1. In the 20‐study pool, the incidence rates per 100 person‐years was higher with saxagliptin versus control for bone fractures [1.1 vs 0.6; incidence rates ratio (95% CI), 1.81 (1.04–3.28)] and hypersensitivity adverse events [1.3 vs 0.8; 1.67 (1.01–2.87)]. Conclusions: Pooled data from 20 studies confirm that saxagliptin has a favourable safety and benefit–risk profile. Copyright © 2013 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 3×
“Recently reported results from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial provide additional information regarding the overall benefit–risk ratio with saxagliptin as well as the risk of AEs of special interest [40].”
BackgroundResultInfluentialSelf-citationSingh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467 · cited 1×
“Significantly higher odds of acute pancreatitis with use of exenatide or sitagliptin were observed in a recent administrative database case–control study [24].”
BackgroundDeFronzo, R. A., Hissa, M. N., Garber, A. J., Luiz Gross, J., Yuyan Duan, R., Ravichandran, S., Chen, R. S., & for the Saxagliptin 014 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1984 · Cited by 416 · cited 1×
“5 and 5 mg once daily, was effective and well tolerated over 24 weeks in improving glycaemic control as monotherapy [5,6] and as add-on therapy to metformin [7], glyburide [8], or thiazolidinedione in patients with T2DM [9].”
BackgroundBarnett, A. H., Charbonnel, B., Donovan, M., & Fleming, D. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.665046 · Cited by 162
Self-citationScirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Price, D. L., Chen, R., Udell, J., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.08.006 · Cited by 106
Self-citation
Cited by
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Deacon, C. F. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00080 · Cited by 428
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
Deacon, C. F. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0399-8 · Cited by 398
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial
Leiter, L. A., Teoh, H., Braunwald, E., Mosenzon, O., Cahn, A., Kumar, K. M. P., Smahelova, A., Hirshberg, B., Stahre, C., Frederich, R., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2868 · Cited by 87
Self-citationAmblee, A., Lious, D., & Fogelfeld, L. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4097 · Cited by 16
Metadata
- Authors
- Hirshberg, B., Parker, A., Edelberg, H., Donovan, M., & Iqbal, N.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2014-10
- Volume
- 30
- Issue
- 7
- Pages
- 556-569
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W1486033897
- Cited by
- 55
- References
- 6
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.